Naoto T Ueno, MD, PhD@teamoncology
Ribociclib Phase III NATALEE demonstrated clinically meaningful benefit in broad population of patients with early-stage breast cancer. Less diarrhea compared to abemaciclib. More compliance ? Includes more Stage II and IBC. https://www.novartis.com/news/media-releases/novartis-kisqali-phase-iii-natalee-trial-meets-primary-endpoint-interim-analysis-demonstrating-clinically-meaningful-benefit-broad-population-patients-early-breast-cancer…
posted at 18:28:51